|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Relugolix in the Phase 3 HERO Study in Men with mHSPC |
| Bertrand Tombal, MD, Ph.D. |
| Alicia Morgans is joined by Bertrand Tombal who is highlighting two subgroup analyses from the phase III HERO trial. They discuss a subgroup analysis assessing the efficacy and safety of relugolix versus leuprolide among men with advanced prostate cancer as well as a subgroup analysis assessing geographical efficacy and safety of relugolix versus leuprolide among men with advanced prostate cancer. |
|
|
|
|
|
|
|
|
|
|
|
| Impact of Concomitant Prostate Cancer Therapy of Relugolix in Men with Advanced Prostate Cancer
|
| Daniel J. George, MD
|
| Daniel George and Neal Shore, co-investigators of the Phase III HERO Trial, join Alicia Morgans recapping the 2021 GU ASCO analysis that Daniel George presented on the efficacy and safety of relugolix vs leuprolide in men with advanced prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
| Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer - The TITAN Study
|
| Neeraj Agarwal, MD
|
| In 2019, the first interim analysis of the phase III TITAN trial was reported which led to the approval of apalutamide for metastatic castration-sensitive prostate cancer (mCSPC). In this conversation with Alicia Morgans, Neeraj Agarwal highlights the final overall survival analysis after a median follow-up of 44 months (nearly 4-years) and the final survival analysis Journal of Clinical Oncology publication.
|
|
|
|
|
|
|
|
|
|
|
|
| Intermittent vs Continuous ADT for Patients, A Review of the NCCN Guidelines
|
Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
Christopher Wallis and Zachary Klaassen review the NCCN clinical practice guidelines on prostate cancer. This discussion is the third part of their discussion of androgen deprivation therapy (ADT).
|
|
|
|
|
|
|
|
|
|
|
| Practice Patterns of Metastatic Castration-Sensitive Prostate Cancer in the Veterans Healthcare Administration |
Scott Tagawa, MD and Stephen Freedland, MD
In this conversation with Alicia Morgans, Scott Tagawa and Stephen Freedland highlight real-world evidence of survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) in the Veterans Health Administration system. |
|
|
|
|
|
|
|
|
|
|
| Geographical Assessment of Efficacy and Safety of Relugolix: A Subgroup Analysis from the Randomized, Phase 3 HERO Study vs Leuprolide in Men with Advanced Prostate Cancer |
| Bertrand Tombal, MD, Ph.D. |
| Bertrand Tombal discusses a subgroup analysis of the phase 3 HERO study assessing geographical efficacy and safety of relugolix versus leuprolide among men with advanced prostate cancer. These results are consistent with those of the overall population where relugolix achieved rapid, sustained suppression of testosterone levels that was superior to that with leuprolide, with a similar overall safety and tolerability profile in the two groups. |
|
|
|
|
|
| Efficacy and Safety of Relugolix vs Leuprolide in Men with Advanced Prostate Cancer: Clinical Subgroup Analysis from the Phase 3 HERO Study
|
| Bertrand Tombal, MD, Ph.D.
|
| In this presentation, Bertrand Tombal discusses work assessing the efficacy and safety of relugolix versus leuprolide among men with advanced prostate cancer, a subgroup analysis of the HERO study. Treatment with relugolix was associated with improved castrations rates versus leuprolide in men with a broad range of clinical presentations for advanced prostate cancer.
|
|
|
|
|
|
|
 pression_zone_212" style="position: absolute; width: 730px; height: 292px; left: 116.667px; top: 3285px; display: none;">
|
|
|
|
| A Phase III Study of Apalutamide vs Placebo In Patients with mCSPC Receiving ADT: Final Analysis Results From TITAN
|
| Kim N. Chi, MD
|
| Kim Chi presents the results of the final analysis of efficacy and safety from TITAN trial. With close to 4 years of follow-up, the final analysis of TITAN demonstrated that in a broad population of patients with mCSPC, apalutamide plus ADT provides an improvement in overall survival with a 35% reduction in risk of death, which increased to a 48% reduction after adjusting for patients who crossed over from placebo to apalutamide.
|
|
|
|
|
|
| Survival Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Real-World Evidence Study |
| Stephen Freedland, MD |
Stephen Freedland assesses the utilization and outcomes for patients with mCSPC in the Veterans Health Administration system. These data highlight that most patients with mCSPC in the VHA who initiated treatment between 2014 and 2018 were treated with ADT only, despite level 1 evidence supporting the use of docetaxel and NHT strategies.
|
|
|
|
|
|
| Treatment Selection in mHSPC: Considerations Now and Downstream in an Evolving Therapeutic Landscape |
| Dana Rathkopf, MD |
| Dana Rathkopf, Medical Oncologist at Memorial Sloan Kettering Cancer Center, discusses two presentations: 1) Time to second progression (PFS2) in patients from TITAN with mCSPC by first subsequent therapy (hormonal versus taxane) and 2) Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed mHSPC: A correlative study of E3805 CHAARTED. |
|
|
|
|
|
 |
